Shopping Cart
Remove All
Your shopping cart is currently empty
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $589 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
| Description | Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis. |
| Targets&IC50 | GPVI-Fc:1.37 μg/mL |
| In vitro | Inhibited the binding of GPVI-Fc to collagen immobilized on microtiter plates, glenzocimab (0-100,000 ng/mL) demonstrated an IC50 of 1.37 μg/mL[2]. |
| In vivo | Glenzocimab ( 1-8 mg / kg ; i.v. ) inhibited collagen-induced platelet aggregation in cynomolgus monkeys [ 2 ]. |
| Synonyms | ACT017 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GP6/Glycoprotein-6 |
| Molecular Weight | 48.29 kDa |
| Cas No. | 2101829-58-5 |
| Isotype | Human IgG1-CH1 kappa |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.